PUBLISHER: Fortune Business Insights Pvt. Ltd. | PRODUCT CODE: 2149277
PUBLISHER: Fortune Business Insights Pvt. Ltd. | PRODUCT CODE: 2149277
Incretin based Drugs Market Size, Share, Growth and Global Industry Analysis, Regional Insights and Forecast to 2026-2034
Growth Factors of incretin-based drugs Market
The global incretin-based drugs market size was valued at USD 78.76 billion in 2025 and is projected to grow from USD 96.09 billion in 2026 to USD 480.32 billion by 2034, exhibiting a CAGR of 22.28% during the forecast period. North America dominated the global incretin-based drugs market with a 58.30% market share in 2025, supported by strong adoption of GLP-1 receptor agonists, dual-incretin therapies, obesity treatments, and established healthcare infrastructure. Incretin-based drugs include therapies used for type 2 diabetes, obesity and weight management, and related cardiometabolic conditions.
The market is expanding as the global burden of diabetes and obesity increases and the adoption of GLP-1 receptor agonists and newer dual-incretin therapies accelerates. The 2025 market value was USD 78.76 billion, while the market is expected to reach USD 96.09 billion in 2026 and USD 480.32 billion in 2034. Major companies include Novo Nordisk A/S, Eli Lilly and Company, Boehringer Ingelheim International GmbH, and Merck & Co., Inc.
MARKET DEFINITION AND SCOPE
Incretin-based drugs are prescription medicines that act through incretin-related pathways to improve glucose regulation, support weight management, and address broader cardiometabolic conditions. The market includes GLP-1 receptor agonists, DPP-4 inhibitors/gliptins, and other incretin-based therapies. The scope covers applications in type 2 diabetes, obesity/weight management, and other indications, along with branded and generic products.
The market also includes oral and parenteral administration routes and distribution through retail pharmacies and drug stores, hospital pharmacies, online pharmacies, and other channels. Increasing product innovation, broader indications, and expanding access are influencing the market's development.
MARKET DYNAMICS
Drivers
The rising global burden of type 2 diabetes and obesity is a major market driver. Increasing diagnosis rates create a large population requiring long-term treatment, supporting recurring demand for incretin-based therapies. The expansion of GLP-1 and dual-incretin products into obesity and cardiometabolic care is also increasing their utilization.
Another important driver is the growing adoption of premium GLP-1 therapies. Increasing prescription penetration and broader availability in developed and emerging markets are supporting market expansion. The continued development of therapies for additional patient populations is further increasing the addressable market.
Trends
A major trend is the shift from DPP-4 inhibitors toward GLP-1 receptor agonists and dual-incretin therapies. GLP-1 products are increasingly used because of their glucose-control and weight-management benefits. Oral incretin development is also becoming increasingly important.
Restraints
High treatment costs and payer budget pressures remain important restraints. Premium GLP-1 and dual-incretin therapies can create substantial costs for patients and healthcare systems, resulting in reimbursement restrictions, prior authorization, and eligibility requirements in some markets.
Impact of COVID-19
The pandemic affected healthcare access, diagnosis, and treatment patterns worldwide. However, the underlying need for chronic diabetes treatment remained, while subsequent improvements in healthcare delivery and prescription access supported the continued development of the market.
SEGMENTATION ANALYSIS
By drug class, GLP-1 receptor agonists dominated the market in 2025, supported by strong adoption in diabetes, obesity, and cardiometabolic care. DPP-4 inhibitors/gliptins remain an established therapy category, while newer incretin products are expanding the competitive landscape.
By indication, type 2 diabetes dominated the market in 2025, reflecting the large treated population and established use of incretin therapies for long-term glycemic control. The obesity/weight management segment is expanding rapidly as GLP-1 and dual-incretin treatments gain wider acceptance.
By type, the branded segment dominated in 2025, supported by products such as Ozempic, Wegovy, Rybelsus, Mounjaro, Zepbound, and Trulicity. By route of administration, parenteral products held the leading position in 2025, while oral therapies are expanding with continued product development.
By age group, adults dominated the market in 2025, owing to the larger adult diabetes and obesity treatment population. By distribution channel, retail pharmacies and drug stores dominated in 2025, supported by chronic prescription refills and broad patient accessibility.
REGIONAL INSIGHTS
North America dominated the market, reaching USD 45.92 billion in 2025, compared with USD 36.64 billion in 2024. The region benefits from high adoption of GLP-1 and dual-incretin products and strong demand for obesity treatments.
Europe is expected to expand at a 19.96% CAGR during the forecast period. Asia Pacific is expected to reach USD 16.72 billion in 2026, supported by its large diabetes population and increasing access to incretin therapies. Latin America and the Middle East & Africa are also expected to experience continued growth.
COMPETITIVE LANDSCAPE
The global market is highly concentrated around major branded pharmaceutical companies. Key players include Novo Nordisk A/S, Eli Lilly and Company, Novartis AG, AstraZeneca, Boehringer Ingelheim International GmbH, Merck & Co., Inc., Teva Pharmaceutical Industries Ltd., Sanofi, Takeda Pharmaceutical Company Limited, and Biocon. Companies are focusing on innovative GLP-1 products, dual-incretin therapies, oral formulations, manufacturing expansion, and broader market access.
REPORT COVERAGE
The report covers the global incretin-based drugs market size and forecast for 2025, 2026, and 2034, along with market dynamics, segmentation by drug class, indication, type, route of administration, age group, and distribution channel. It also examines regional markets, competitive developments, product innovation, regulatory developments, collaborations, acquisitions, and major industry developments.
CONCLUSION
The global incretin-based drugs market is projected to expand from USD 78.76 billion in 2025 to USD 96.09 billion in 2026 and USD 480.32 billion by 2034, at a 22.28% CAGR. Rising diabetes and obesity prevalence, increasing adoption of GLP-1 and dual-incretin therapies, broader cardiometabolic applications, and growing access to innovative treatments are supporting market expansion. At the same time, high treatment costs, reimbursement constraints, and manufacturing capacity requirements remain important factors influencing future market development.
Segmentation By Drug Class, Indication, Type, Route of Administration, Age Group, Distribution Channel, and Region
By Drug Class
- GLP-1 Receptor Agonists
- DPP-4 INHIBITORS/GLIPTINS
- Others
By Indication
- Type 2 Diabetes
- Obesity/Weight Management
- Others
By Type
- Branded
- Generic
By Route of Administration
- Oral
- Parenteral
By Age Group
- Adults
- Pediatrics
By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies & Drug Stores
- Online Pharmacies
- Others
By Region
- North America (By Drug Class, Indication, Type, Route of Administration, Age Group, Distribution Channel, and Country)
- U.S.
- Canada
- Europe (By Drug Class, Indication, Type, Route of Administration, Age Group, Distribution Channel, and Country/Sub-region)
- Germany
- U.K.
- France
- Spain
- Italy
- Scandinavia
- Rest of Europe
- Asia Pacific (By Drug Class, Indication, Type, Route of Administration, Age Group, Distribution Channel, and Country/Sub-region)
- China
- Japan
- India
- Australia
- Southeast Asia
- Rest of Asia Pacific
- Latin America (By Drug Class, Indication, Type, Route of Administration, Age Group, Distribution Channel, and Country/Sub-region)
- Brazil
- Mexico
- Rest of Latin America
- Middle East & Africa (By Drug Class, Indication, Type, Route of Administration, Age Group, Distribution Channel, and Country/Sub-region)
- GCC
- South Africa
- Rest of the Middle East & Africa
Table of Content
1. Introduction
- 1.1. Research Scope
- 1.2. Market Segmentation
- 1.3. Research Methodology
- 1.4. Definitions and Assumptions
2. Executive Summary
3. Market Dynamics
- 3.1. Market Drivers
- 3.2. Market Restraints
- 3.3. Market Opportunities
- 3.4. Market Challenges
- 3.5. Market Trends
4. Key Insights
- 4.1. Prevalence of Key Diseases, By Key Countries/Region
- 4.2. Key Industry Developments (Mergers, Acquisitions, Partnerships, etc.)
- 4.3. New Product Launches, By Key Players
- 4.4. Pipeline Analysis, By Key Players
- 4.5. Regulatory & Reimbursement Scenario, By Key Countries/Region
5. Global Incretin-based Drugs Market Analysis, Insights and Forecast, 2021-2034
- 5.1. Market Analysis, Insights and Forecast - By Drug Class
- 5.1.1. GLP-1 Receptor Agonists
- 5.1.2. DPP-4 INHIBITORS/GLIPTINS
- 5.1.3. Others
- 5.2. Market Analysis, Insights and Forecast - By Indication
- 5.2.1. Type 2 Diabetes
- 5.2.2. Obesity/Weight Management
- 5.2.3. Others
- 5.3. Market Analysis, Insights and Forecast - By Route of Administration
- 5.3.1. Oral
- 5.3.2. Parenteral
- 5.4. Market Analysis, Insights and Forecast - By Type
- 5.4.1. Branded
- 5.4.2. Generic
- 5.5. Market Analysis, Insights and Forecast - By Age Group
- 5.5.1. Pediatrics
- 5.5.2. Adults
- 5.6. Market Analysis, Insights and Forecast - By Distribution Channel
- 5.6.1. Hospital Pharmacies
- 5.6.2. Retail Pharmacies & Drug Stores
- 5.6.3. Online Pharmacies
- 5.6.4. Others
- 5.7. Market Analysis, Insights and Forecast - Region
- 5.7.1. North America
- 5.7.2. Europe
- 5.7.3. Asia Pacific
- 5.7.4. Latin America
- 5.7.5. Middle East & Africa
6. North America Incretin-based Drugs Market Analysis, Insights and Forecast, 2021-2034
- 6.1. Market Analysis, Insights and Forecast - By Drug Class
- 6.1.1. GLP-1 Receptor Agonists
- 6.1.2. DPP-4 INHIBITORS/GLIPTINS
- 6.1.3. Others
- 6.2. Market Analysis, Insights and Forecast - By Indication
- 6.2.1. Type 2 Diabetes
- 6.2.2. Obesity/Weight Management
- 6.2.3. Others
- 6.3. Market Analysis, Insights and Forecast - By Route of Administration
- 6.3.1. Oral
- 6.3.2. Parenteral
- 6.4. Market Analysis, Insights and Forecast - By Type
- 6.4.1. Branded
- 6.4.2. Generic
- 6.5. Market Analysis, Insights and Forecast - By Age Group
- 6.5.1. Pediatrics
- 6.5.2. Adults
- 6.6. Market Analysis, Insights and Forecast - By Distribution Channel
- 6.6.1. Hospital Pharmacies
- 6.6.2. Retail Pharmacies & Drug Stores
- 6.6.3. Online Pharmacies
- 6.6.4. Others
- 6.7. Market Analysis, Insights and Forecast - By Country
- 6.7.1. U.S.
- 6.7.2. Canada
7. Europe Incretin-based Drugs Market Analysis, Insights and Forecast, 2021-2034
- 7.1. Market Analysis, Insights and Forecast - By Drug Class
- 7.1.1. GLP-1 Receptor Agonists
- 7.1.2. DPP-4 INHIBITORS/GLIPTINS
- 7.1.3. Others
- 7.2. Market Analysis, Insights and Forecast - By Indication
- 7.2.1. Type 2 Diabetes
- 7.2.2. Obesity/Weight Management
- 7.2.3. Others
- 7.3. Market Analysis, Insights and Forecast - By Route of Administration
- 7.3.1. Oral
- 7.3.2. Parenteral
- 7.4. Market Analysis, Insights and Forecast - By Type
- 7.4.1. Branded
- 7.4.2. Generic
- 7.5. Market Analysis, Insights and Forecast - By Age Group
- 7.5.1. Pediatrics
- 7.5.2. Adults
- 7.6. Market Analysis, Insights and Forecast - By Distribution Channel
- 7.6.1. Hospital Pharmacies
- 7.6.2. Retail Pharmacies & Drug Stores
- 7.6.3. Online Pharmacies
- 7.6.4. Others
- 7.7. Market Analysis, Insights and Forecast - By Country/ Sub-Region
- 7.7.1. U.K.
- 7.7.2. Germany
- 7.7.3. France
- 7.7.4. Italy
- 7.7.5. Spain
- 7.7.6. Scandinavia
- 7.7.7. Rest of Europe
8. Asia Pacific Incretin-based Drugs Market Analysis, Insights and Forecast, 2021-2034
- 8.1. Market Analysis, Insights and Forecast - By Drug Class
- 8.1.1. GLP-1 Receptor Agonists
- 8.1.2. DPP-4 INHIBITORS/GLIPTINS
- 8.1.3. Others
- 8.2. Market Analysis, Insights and Forecast - By Indication
- 8.2.1. Type 2 Diabetes
- 8.2.2. Obesity/Weight Management
- 8.2.3. Others
- 8.3. Market Analysis, Insights and Forecast - By Route of Administration
- 8.3.1. Oral
- 8.3.2. Parenteral
- 8.4. Market Analysis, Insights and Forecast - By Type
- 8.4.1. Branded
- 8.4.2. Generic
- 8.5. Market Analysis, Insights and Forecast - By Age Group
- 8.5.1. Pediatrics
- 8.5.2. Adults
- 8.6. Market Analysis, Insights and Forecast - By Distribution Channel
- 8.6.1. Hospital Pharmacies
- 8.6.2. Retail Pharmacies & Drug Stores
- 8.6.3. Online Pharmacies
- 8.6.4. Others
- 8.7. Market Analysis, Insights and Forecast - By Country/ Sub-Region
- 8.7.1. China
- 8.7.2. Japan
- 8.7.3. India
- 8.7.4. Australia
- 8.7.5. Southeast Asia
- 8.7.6. Rest of Asia Pacific
9. Latin America Incretin-based Drugs Market Analysis, Insights and Forecast, 2021-2034
- 9.1. Market Analysis, Insights and Forecast - By Drug Class
- 9.1.1. GLP-1 Receptor Agonists
- 9.1.2. DPP-4 INHIBITORS/GLIPTINS
- 9.1.3. Others
- 9.2. Market Analysis, Insights and Forecast - By Indication
- 9.2.1. Type 2 Diabetes
- 9.2.2. Obesity/Weight Management
- 9.2.3. Others
- 9.3. Market Analysis, Insights and Forecast - By Route of Administration
- 9.3.1. Oral
- 9.3.2. Parenteral
- 9.4. Market Analysis, Insights and Forecast - By Type
- 9.4.1. Branded
- 9.4.2. Generic
- 9.5. Market Analysis, Insights and Forecast - By Age Group
- 9.5.1. Pediatrics
- 9.5.2. Adults
- 9.6. Market Analysis, Insights and Forecast - By Distribution Channel
- 9.6.1. Hospital Pharmacies
- 9.6.2. Retail Pharmacies & Drug Stores
- 9.6.3. Online Pharmacies
- 9.6.4. Others
- 9.7. Market Analysis, Insights and Forecast - By Country/ Sub-Region
- 9.7.1. Brazil
- 9.7.2. Mexico
- 9.7.3. Rest of Latin America
10. Middle East & Africa Incretin-based Drugs Market Analysis, Insights and Forecast, 2021-2034
- 10.1. Market Analysis, Insights and Forecast - By Drug Class
- 10.1.1. GLP-1 Receptor Agonists
- 10.1.2. DPP-4 INHIBITORS/GLIPTINS
- 10.1.3. Others
- 10.2. Market Analysis, Insights and Forecast - By Indication
- 10.2.1. Type 2 Diabetes
- 10.2.2. Obesity/Weight Management
- 10.2.3. Others
- 10.3. Market Analysis, Insights and Forecast - By Route of Administration
- 10.3.1. Oral
- 10.3.2. Parenteral
- 10.4. Market Analysis, Insights and Forecast - By Type
- 10.4.1. Branded
- 10.4.2. Generic
- 10.5. Market Analysis, Insights and Forecast - By Age Group
- 10.5.1. Pediatrics
- 10.5.2. Adults
- 10.6. Market Analysis, Insights and Forecast - By Distribution Channel
- 10.6.1. Hospital Pharmacies
- 10.6.2. Retail Pharmacies & Drug Stores
- 10.6.3. Online Pharmacies
- 10.6.4. Others
- 10.7. Market Analysis, Insights and Forecast - By Country/ Sub-Region
- 10.7.1. GCC
- 10.7.2. South Africa
- 10.7.3. Rest of the Middle East & Africa
11. Competitive Analysis
- 11.1. Global Market Share Analysis (2025)
- 11.2. Company Profiles
- 11.2.1. Novo Nordisk A/S
- 11.2.2. Eli Lilly and Company
- 11.2.3. Novartis AG
- 11.2.4. AstraZeneca
- 11.2.5. Boehringer Ingelheim International GmbH
- 11.2.6. Merck & Co., Inc.
- 11.2.7. Teva Pharmaceutical Industries Ltd.
- 11.2.8. Sanofi
- 11.2.9. Takeda Pharmaceutical Company Limited
- 11.2.10. Biocon
List of Tables
- Table 1: Global Incretin-based Drugs Market Revenue (USD billion) Forecast, By Drug Class, 2021-2034
- Table 2: Global Incretin-based Drugs Market Revenue (USD billion) Forecast, By Indication, 2021-2034
- Table 3: Global Incretin-based Drugs Market Revenue (USD billion) Forecast, By Route of Administration, 2021-2034
- Table 4: Global Incretin-based Drugs Market Revenue (USD billion) Forecast, By Type, 2021-2034
- Table 5: Global Incretin-based Drugs Market Revenue (USD billion) Forecast, By Age Group, 2021-2034
- Table 6: Global Incretin-based Drugs Market Revenue (USD billion) Forecast, By Distribution Channel, 2021-2034
- Table 7: Global Incretin-based Drugs Market Revenue (USD billion) Forecast, By Region, 2021-2034
- Table 8: North America Incretin-based Drugs Market Revenue (USD billion) Forecast, By Drug Class, 2021-2034
- Table 9: North America Incretin-based Drugs Market Revenue (USD billion) Forecast, By Indication, 2021-2034
- Table 10: North America Incretin-based Drugs Market Revenue (USD billion) Forecast, By Route of Administration, 2021-2034
- Table 11: North America Incretin-based Drugs Market Revenue (USD billion) Forecast, By Type, 2021-2034
- Table 12: North America Incretin-based Drugs Market Revenue (USD billion) Forecast, By Age Group, 2021-2034
- Table 13: North America Incretin-based Drugs Market Revenue (USD billion) Forecast, By Distribution Channel, 2021-2034
- Table 14: North America Incretin-based Drugs Market Revenue (USD billion) Forecast, by Country, 2021-2034
- Table 15: Europe Incretin-based Drugs Market Revenue (USD billion) Forecast, By Drug Class, 2021-2034
- Table 16: Europe Incretin-based Drugs Market Revenue (USD billion) Forecast, By Indication, 2021-2034
- Table 17: Europe Incretin-based Drugs Market Revenue (USD billion) Forecast, By Route of Administration, 2021-2034
- Table 18: Europe Incretin-based Drugs Market Revenue (USD billion) Forecast, By Type, 2021-2034
- Table 19: Europe Incretin-based Drugs Market Revenue (USD billion) Forecast, By Age Group, 2021-2034
- Table 20: Europe Incretin-based Drugs Market Revenue (USD billion) Forecast, By Distribution Channel, 2021-2034
- Table 21: Europe Incretin-based Drugs Market Revenue (USD billion) Forecast, by Country/ Sub-region, 2021-2034
- Table 22: Asia Pacific Incretin-based Drugs Market Revenue (USD billion) Forecast, By Drug Class, 2021-2034
- Table 23: Asia Pacific Incretin-based Drugs Market Revenue (USD billion) Forecast, By Indication, 2021-2034
- Table 24: Asia Pacific Incretin-based Drugs Market Revenue (USD billion) Forecast, By Route of Administration, 2021-2034
- Table 25: Asia Pacific Incretin-based Drugs Market Revenue (USD billion) Forecast, By Type, 2021-2034
- Table 26: Asia Pacific Incretin-based Drugs Market Revenue (USD billion) Forecast, By Age Group, 2021-2034
- Table 27: Asia Pacific Incretin-based Drugs Market Revenue (USD billion) Forecast, By Distribution Channel, 2021-2034
- Table 28: Asia Pacific Incretin-based Drugs Market Revenue (USD billion) Forecast, by Country/ Sub-region, 2021-2034
- Table 29: Latin America Incretin-based Drugs Market Revenue (USD billion) Forecast, By Drug Class, 2021-2034
- Table 30: Latin America Incretin-based Drugs Market Revenue (USD billion) Forecast, By Indication, 2021-2034
- Table 31: Latin America Incretin-based Drugs Market Revenue (USD billion) Forecast, By Route of Administration, 2021-2034
- Table 32: Latin America Incretin-based Drugs Market Revenue (USD billion) Forecast, By Type, 2021-2034
- Table 33: Latin America Incretin-based Drugs Market Revenue (USD billion) Forecast, By Age Group, 2021-2034
- Table 34: Latin America Incretin-based Drugs Market Revenue (USD billion) Forecast, By Distribution Channel, 2021-2034
- Table 35: Latin America Incretin-based Drugs Market Revenue (USD billion) Forecast, by Country/ Sub-region, 2021-2034
- Table 36: Middle East & Africa Incretin-based Drugs Market Revenue (USD billion) Forecast, By Drug Class, 2021-2034
- Table 37: Middle East & Africa Incretin-based Drugs Market Revenue (USD billion) Forecast, By Indication, 2021-2034
- Table 38: Middle East & Africa Incretin-based Drugs Market Revenue (USD billion) Forecast, By Route of Administration, 2021-2034
- Table 39: Middle East & Africa Incretin-based Drugs Market Revenue (USD billion) Forecast, By Type, 2021-2034
- Table 40: Middle East & Africa Incretin-based Drugs Market Revenue (USD billion) Forecast, By Age Group, 2021-2034
- Table 41: Middle East & Africa Incretin-based Drugs Market Revenue (USD billion) Forecast, By Distribution Channel, 2021-2034
- Table 42: Middle East & Africa Incretin-based Drugs Market Revenue (USD billion) Forecast, by Country/ Sub-region, 2021-2034
List of Figures
- Figure 1: Global Incretin-based Drugs Market Revenue Breakdown (USD billion, %) By Region, 2025 & 2034
- Figure 2: Global Incretin-based Drugs Market Value Share (%), By Drug Class, 2025 & 2034
- Figure 3: Global Incretin-based Drugs Market Value Share (%), By Indication, 2025 & 2034
- Figure 4: Global Incretin-based Drugs Market Value Share (%), By Route of Administration, 2025 & 2034
- Figure 5: Global Incretin-based Drugs Market Value Share (%), By Type, 2025 & 2034
- Figure 6: Global Incretin-based Drugs Market Value Share (%), By Age Group, 2025 & 2034
- Figure 7: Global Incretin-based Drugs Market Value Share (%), By Distribution Channel, 2025 & 2034
- Figure 8: Global Incretin-based Drugs Market Value Share (%), By Region, 2025 & 2034
- Figure 9: North America Incretin-based Drugs Market Value (USD billion), By Drug Class, 2025 & 2034
- Figure 10: North America Incretin-based Drugs Market Value Share (%), By Drug Class, 2025
- Figure 11: North America Incretin-based Drugs Market Value (USD billion), By Indication, 2025 & 2034
- Figure 12: North America Incretin-based Drugs Market Value Share (%), By Indication, 2025
- Figure 13: North America Incretin-based Drugs Market Value (USD billion), By Route of Administration, 2025 & 2034
- Figure 14: North America Incretin-based Drugs Market Value Share (%), By Route of Administration, 2025
- Figure 15: North America Incretin-based Drugs Market Value (USD billion), By Type, 2025 & 2034
- Figure 16: North America Incretin-based Drugs Market Value Share (%), By Type, 2025
- Figure 17: North America Incretin-based Drugs Market Value (USD billion), By Age Group, 2025 & 2034
- Figure 18: North America Incretin-based Drugs Market Value Share (%), By Age Group, 2025
- Figure 19: North America Incretin-based Drugs Market Value (USD billion), By Distribution Channel, 2025 & 2034
- Figure 20: North America Incretin-based Drugs Market Value Share (%), By Distribution Channel, 2025
- Figure 21: North America Incretin-based Drugs Market Value (USD billion), by Country, 2025 & 2034
- Figure 22: North America Incretin-based Drugs Market Value Share (%), by Country, 2025
- Figure 23: Europe Incretin-based Drugs Market Value (USD billion), By Drug Class, 2025 & 2034
- Figure 24: Europe Incretin-based Drugs Market Value Share (%), By Drug Class, 2025
- Figure 25: Europe Incretin-based Drugs Market Value (USD billion), By Indication, 2025 & 2034
- Figure 26: Europe Incretin-based Drugs Market Value Share (%), By Indication, 2025
- Figure 27: Europe Incretin-based Drugs Market Value (USD billion), By Route of Administration, 2025 & 2034
- Figure 28: Europe Incretin-based Drugs Market Value Share (%), By Route of Administration, 2025
- Figure 29: Europe Incretin-based Drugs Market Value (USD billion), By Type, 2025 & 2034
- Figure 30: Europe Incretin-based Drugs Market Value Share (%), By Type, 2025
- Figure 31: Europe Incretin-based Drugs Market Value (USD billion), By Age Group, 2025 & 2034
- Figure 32: Europe Incretin-based Drugs Market Value Share (%), By Age Group, 2025
- Figure 33: Europe Incretin-based Drugs Market Value (USD billion), By Distribution Channel, 2025 & 2034
- Figure 34: Europe Incretin-based Drugs Market Value Share (%), By Distribution Channel, 2025
- Figure 35: Europe Incretin-based Drugs Market Value (USD billion), by Country/ Sub-region, 2025 & 2034
- Figure 36: Europe Incretin-based Drugs Market Value Share (%), by Country/ Sub-region, 2025
- Figure 37: Asia Pacific Incretin-based Drugs Market Value (USD billion), By Drug Class, 2025 & 2034
- Figure 38: Asia Pacific Incretin-based Drugs Market Value Share (%), By Drug Class, 2025
- Figure 39: Asia Pacific Incretin-based Drugs Market Value (USD billion), By Indication, 2025 & 2034
- Figure 40: Asia Pacific Incretin-based Drugs Market Value Share (%), By Indication, 2025
- Figure 41: Asia Pacific Incretin-based Drugs Market Value (USD billion), By Route of Administration, 2025 & 2034
- Figure 42: Asia Pacific Incretin-based Drugs Market Value Share (%), By Route of Administration, 2025
- Figure 43: Asia Pacific Incretin-based Drugs Market Value (USD billion), By Type, 2025 & 2034
- Figure 44: Asia Pacific Incretin-based Drugs Market Value Share (%), By Type, 2025
- Figure 45: Asia Pacific Incretin-based Drugs Market Value (USD billion), By Age Group, 2025 & 2034
- Figure 46: Asia Pacific Incretin-based Drugs Market Value Share (%), By Age Group, 2025
- Figure 47: Asia Pacific Incretin-based Drugs Market Value (USD billion), By Distribution Channel, 2025 & 2034
- Figure 48: Asia Pacific Incretin-based Drugs Market Value Share (%), By Distribution Channel, 2025
- Figure 49: Asia Pacific Incretin-based Drugs Market Value (USD billion), by Country/ Sub-region, 2025 & 2034
- Figure 50: Asia Pacific Incretin-based Drugs Market Value Share (%), by Country/ Sub-region, 2025
- Figure 51: Latin America Incretin-based Drugs Market Value (USD billion), By Drug Class, 2025 & 2034
- Figure 52: Latin America Incretin-based Drugs Market Value Share (%), By Drug Class, 2025
- Figure 53: Latin America Incretin-based Drugs Market Value (USD billion), By Indication, 2025 & 2034
- Figure 54: Latin America Incretin-based Drugs Market Value Share (%), By Indication, 2025
- Figure 55: Latin America Incretin-based Drugs Market Value (USD billion), By Route of Administration, 2025 & 2034
- Figure 56: Latin America Incretin-based Drugs Market Value Share (%), By Route of Administration, 2025
- Figure 57: Latin America Incretin-based Drugs Market Value (USD billion), By Type, 2025 & 2034
- Figure 58: Latin America Incretin-based Drugs Market Value Share (%), By Type, 2025
- Figure 59: Latin America Incretin-based Drugs Market Value (USD billion), By Age Group, 2025 & 2034
- Figure 60: Latin America Incretin-based Drugs Market Value Share (%), By Age Group, 2025
- Figure 61: Latin America Incretin-based Drugs Market Value (USD billion), By Distribution Channel, 2025 & 2034
- Figure 62: Latin America Incretin-based Drugs Market Value Share (%), By Distribution Channel, 2025
- Figure 63: Latin America Incretin-based Drugs Market Value (USD billion), by Country/ Sub-region, 2025 & 2034
- Figure 64: Latin America Incretin-based Drugs Market Value Share (%), by Country/ Sub-region, 2025
- Figure 65: Middle East & Africa Incretin-based Drugs Market Value (USD billion), By Drug Class, 2025 & 2034
- Figure 66: Middle East & Africa Incretin-based Drugs Market Value Share (%), By Drug Class, 2025
- Figure 67: Middle East & Africa Incretin-based Drugs Market Value (USD billion), By Indication, 2025 & 2034
- Figure 68: Middle East & Africa Incretin-based Drugs Market Value Share (%), By Indication, 2025
- Figure 69: Middle East & Africa Incretin-based Drugs Market Value (USD billion), By Route of Administration, 2025 & 2034
- Figure 70: Middle East & Africa Incretin-based Drugs Market Value Share (%), By Route of Administration, 2025
- Figure 71: Middle East & Africa Incretin-based Drugs Market Value (USD billion), By Type, 2025 & 2034
- Figure 72: Middle East & Africa Incretin-based Drugs Market Value Share (%), By Type, 2025
- Figure 73: Middle East & Africa Incretin-based Drugs Market Value (USD billion), By Age Group, 2025 & 2034
- Figure 74: Middle East & Africa Incretin-based Drugs Market Value Share (%), By Age Group, 2025
- Figure 75: Middle East & Africa Incretin-based Drugs Market Value (USD billion), By Distribution Channel, 2025 & 2034
- Figure 76: Middle East & Africa Incretin-based Drugs Market Value Share (%), By Distribution Channel, 2025
- Figure 77: Middle East & Africa Incretin-based Drugs Market Value (USD billion), by Country/ Sub-region, 2025 & 2034
- Figure 78: Middle East & Africa Incretin-based Drugs Market Value Share (%), by Country/ Sub-region, 2025
- Figure 79: Global Incretin-based Drugs Market Share (%), by Company, 2025
